Forbes March 12, 2025
In an era where artificial intelligence (AI) is transforming nearly every industry, the intersection of AI and drug discovery is emerging as one of the most promising frontiers. The recent rise of companies like Lila Sciences and Recursion Pharmaceuticals reflects growing confidence among investors and researchers that AI could unlock previously unattainable scientific insights, accelerating drug discovery and reshaping scientific exploration.
Lila Sciences, with its ambitious goal of creating “scientific superintelligence,” and Recursion Pharmaceuticals, with its AI-powered platform for mapping human biology, are at the forefront of this movement. Backed by hundreds of millions in funding and leveraging the latest advancements in AI scaling laws, these companies are positioning themselves to drive breakthroughs in medicine, materials science, and beyond. Most...
Today's Sponsors
Today's Sponsor